EUVIMEDEUVIMED entdecken
Crossref

Practical Advances in the Diagnosis of Haemophilia and von Willebrand Disease Including Monitoring of Non‐Factor Replacement Therapies

Annette Bowyer iD, Silmara Montalvão iD, Yesim Dargaud iD

Haemophilia · 16.04.2026

DOI: 10.1111/hae.70224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 16.04.2026. Verfasst von Annette Bowyer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Coagulation, Royal Hallamshire Hospital, Sheffield, UK. Die Arbeit nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional haemophilia therapies act to replace the relevant missing clotting factor, are not interchangeable between haemophilia A and B and cannot be used in patients with high titre inhibitors. Novel non‐replacement factor therapies (NFT) target other endogenous coagulation proteins or anticoagulants such as antithrombin (AT) and tissue factor pathway inhibitor (TFPI) to rebalance haemostasis. As such, pharmaceutical clinical trials of these molecules have enrolled patients with haemophilia A or B, with and without inhibitors. The requirement for monitoring the efficacy of NFTs is greatly reduced compared to replacement therapy and global assays such as thrombin generation assay (TGA) have been used extensively in clinical trials to indicate improvement to haemostasis. Comprehensive haemophilia care, including access to and laboratory monitoring of replacement and NFTs, is well established in high income countries, but there are profound global inequities in the diagnosis and treatment of haemophilia which still need to be remedied. The authors examine the challenges of haemophilia and von Willebrand diagnosis and monitoring of NFTs using conventional and global assays of haemostasis.

Schlagwörter

Stichwörter der Autor:innen

TFPIantithrombinfactor IXfactor VIIIhaemophilianon‐replacementthrombin generation

Autor:innen und Institutionen

  • Department of Coagulation, Royal Hallamshire Hospital, Sheffield, UK.
  • Laboratory Hemostasis and Thrombosis, Hematology and Hemotherapy Center, University of Campinas UNICAMP, Campinas, São Paulo, Brazil.
  • French Reference Center for Haemophilia and Clinical Haemostasis Unit, Louis Pradel Hospital, Lyon, France.
  • Faculty of Medicine Lyon Est, UR4609 Research Laboratory on Haemophilia, University Claude Bernard Lyon 1, Lyon, France.

ORCID-Profile: Annette Bowyer, Silmara Montalvão, Yesim Dargaud

Zitieren

APA

Bowyer, A., Montalvão, S., & Dargaud, Y. (2026). Practical Advances in the Diagnosis of Haemophilia and von Willebrand Disease Including Monitoring of Non‐Factor Replacement Therapies. Haemophilia. https://doi.org/10.1111/hae.70224

Vancouver

Bowyer A, Montalvão S, Dargaud Y. Practical Advances in the Diagnosis of Haemophilia and von Willebrand Disease Including Monitoring of Non‐Factor Replacement Therapies. Haemophilia. 2026. doi:10.1111/hae.70224

BibTeX
@article{Bowyer2026,
  author = {Bowyer, Annette and Montalvão, Silmara and Dargaud, Yesim},
  title = {Practical Advances in the Diagnosis of Haemophilia and von Willebrand Disease Including Monitoring of Non‐Factor Replacement Therapies},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70224}
}
Kostenlos starten →